RadioMedix是一家临床阶段的放射药物公司，宣布由Fusion Pharmaceuticals收购其225Ac-PSMA-I&T资产。Fusion Pharmaceuticals是一家临床阶段肿瘤学公司，专注于开发作为精准药物的下一代放射性药物。225Ac-PSMA-I&T目前正在进行一项医师赞助的新药(IND)II期研究(简称TATCIST试验)下进行评估。RadioMedix还将为Fusion提供制造...
药品名称 225Ac-PSMA I&T; 225Ac-PSMA-I&T; Ac225-PSMA I&T; FPI-2265 药品类别 创新药; 化药; 小分子; 放射性药物 靶点 prostate-specific membrane antigen (PSMA) 作用机制 225Ac标记的放射性药物 药品简介 -- 研发机构 Fusion Pharmaceuticals (AstraZeneca) ;Excel Diagnostics and Nuclear On...
The emission of the first alpha particle from 225Ac results in dissociation of the decay isotope 221Fr from the metal chelate, leading to a biodistribution of 221Fr and its radioactive decay products that may differ from the biodistribution of the parent compound 225Ac-PSMA I&T. Aim: We ...
European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:1262–1263 https://doi.org/10.1007/s00259-020-05023-2 IMAGE OF THE MONTH Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC Harun Ilhan1 & Astrid Gosewisch1 & Guido Böning1 & Friederike ...
13. Kratochwil C,F.Giesel,F.Bruchertseifer, M. Rius, C. Aposto- lidis,U.Haberkorn,A.Morgenstern.Ac-225-PSMA617:asingle center experience of 40 patients receiving PSMA-targetedalphatherapy. Soc Nucl Med 2016doi:10.2967/jn...
225Ac- PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med 2016;57:1941-1944.Kratochwil, C.; Bruchertseifer, F.; Giesel, F.L.; Weis, M.; Verburg, F... K Clemens,B Frank,G Frederik,... 被引量: 11发表: ...
(i.e., DI H2O, MeOH, or a mixture of both) in an Eppendorf tube. This mixture was sonicated for 30 s in a cup-horn sonicator (100% amplitude) to generate a water/oil emulsion. After sonication, 200 µL of vitamin E-TPGS (1 wt % in DI H2O) was added immediately to the ...
PSMA (177Lu-PSMA) and actinium-225 labeled PSMA (225Ac-PSMA) RNT in patients with mCRPC. While promising results have been achieved, this field is still in development. In this review, we have summarized and discussed the clinical data of177Lu-PSMA and225Ac-PSMA RNT in patients with ...
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016, 57, 1941–1944. [CrossRef] [PubMed] 9. Morgenstern, A.; Bruchertseifer, F.; Apostolidis, C. Bismuth-213 and actinium-225—Generator performance and evolving ...
Part 2 (P2) randomizes 1:1 between 45 and 60 kBq/kg in patients with CRPC without prior exposure to Lu-177-PSMA (-617 or -I&T). Part 3 (P3) is a Bayesian Optimal Interval (BOIN) design dose-escalation protocol (45, 55, and 60 kBq/kg, with optional dose expansion) for ...